Xilio Therapeutics, Inc. (XLO) Misses Q2 EPS by 1c

Xilio Therapeutics, Inc. (NASDAQ: XLO) reported Q2 EPS of ($0.24), $0.01 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $2.4 million versus the consensus estimate of $30 million.

For earnings history and earnings-related data on Xilio Therapeutics, Inc. (XLO) click here.

You May Also Be Interested In

• UBS Assumes Interactive Brokers Group (IBKR) at Neutral, 'A Best-in-Class, Yet Fairly Valued Brokerage'
• BTIG Upgrades Tidewater Inc (TDW) to Buy, 'Increasing Activity Set To Push Dayrates Higher in Key Basins'
• UBS Starts Assembly Biosciences (ASMB) at Buy